IDH1 mutations in glioma cells diminish the canonical enzymatic activity of IDH1 while conferring a neomorphic enzymatic activity: the production of R-2-hydoxyglutarate (2-HG) via the consumption of NADPH [13-16]. This evidence concerns the gene IDH1 and glioma.